Eric I Rossman
Overview
Explore the profile of Eric I Rossman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boulay E, Authier S, Bartko T, Greiter-Wilke A, Leishman D, Li D, et al.
J Pharmacol Toxicol Methods
. 2024 Jul;
129:107543.
PMID: 39019200
Introduction: Corrected QT interval (QTc)is an established biomarker for drug-induced Torsade de Pointe (TdP), but with concerns for a false positive signal. Clinically, JTpc and TpTec have emerged as ECG...
2.
Wisialowski T, Ether N, Foley C, Kleiman R, Koshman Y, Leishman D, et al.
J Pharmacol Toxicol Methods
. 2024 May;
128:107515.
PMID: 38777240
No abstract available.
3.
Stebbeds W, Raniga K, Standing D, Wallace I, Bayliss J, Brown A, et al.
Toxicol Sci
. 2023 Jul;
195(1):61-70.
PMID: 37462734
Cardiovascular toxicity is an important cause of drug failures in the later stages of drug development, early clinical safety assessment, and even postmarket withdrawals. Early-stage in vitro assessment of potential...
4.
Rossman E, Wisialowski T, Vargas H, Valentin J, Rolf M, Roche B, et al.
J Pharmacol Toxicol Methods
. 2023 May;
123:107270.
PMID: 37164235
The ICH E14/S7B Questions and Answers (Q&As) guideline introduces the concept of a "double negative" nonclinical scenario (negative hERG assay and negative in vivo QTc study) to demonstrate that a...
5.
Vargas H, Rossman E, Wisialowski T, Nichols J, Pugsley M, Roche B, et al.
J Pharmacol Toxicol Methods
. 2023 Mar;
121:107265.
PMID: 36997076
Recent updates and modifications to the clinical ICH E14 and nonclinical ICH S7B guidelines, which both relate to the evaluation of drug-induced delayed repolarization risk, provide an opportunity for nonclinical...
6.
Boulay E, Miraucourt L, Pugsley M, Abernathy M, Chui R, Dalton J, et al.
J Pharmacol Toxicol Methods
. 2023 Mar;
121:107266.
PMID: 36963703
Introduction: Characterization of the incidence of spontaneous arrhythmias to identify possible drug-related effects is often an important part of the analysis in safety pharmacology studies using telemetry. Methods: A retrospective...
7.
Fu Y, Taghvafard H, Said M, Rossman E, Collins T, Billiald-Desquand S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Feb;
11(5):640-652.
PMID: 35213797
The use of systems-based pharmacological modeling approaches to characterize mode-of-action and concentration-effect relationships for drugs on specific hemodynamic variables has been demonstrated. Here, we (i) expand a previously developed hemodynamic...
8.
Delaunois A, Abernathy M, Anderson W, Beattie K, Chaudhary K, Coulot J, et al.
Clin Transl Sci
. 2021 Feb;
14(3):1133-1146.
PMID: 33620150
We applied a set of in silico and in vitro assays, compliant with the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm, to assess the risk of chloroquine (CLQ) or hydroxychloroquine...
9.
Rossman E, Cools F, Cordes J, Dhuyvetter D, Doyle J, Friedrichs G, et al.
J Pharmacol Toxicol Methods
. 2020 Jul;
105:106897.
PMID: 32663523
Introduction: Alterations in cardiac contractility can have significant clinical implications, highlighting the need for early detection of potential liabilities. Pre-clinical methods to assess contractility are typically invasive and their translation...
10.
Boulay E, Abernathy M, Chui R, Friedrichs G, Gendron-Parra N, Greiter-Wilke A, et al.
Int J Toxicol
. 2018 Dec;
38(1):23-32.
PMID: 30567462
Introduction: Based on the ICH S7B and E14 guidance documents, QT interval (QTc) is used as the primary in vivo biomarker to assess the risk of drug-induced torsades de pointes...